Neuroendocrine tumours of the lung other than SCLC

Lung neuroendocrine malignancies represent around 25% of all lung cancers, however, awareness of lung NETs remains low among thoracic specialists who are often involved in the evaluation and early treatment of these patients. Diagnosis and classification can be challenging, particularly for high and low/intermediate grade lung NET types. As for rare lung NETs, bronchial carcinoid tumors, there has been some important advances in understanding of the molecular pathogenesis and development of novel treatment options with evidence on their efficacy.